Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis

Li Shen, Hongchun Peng, Ran Peng, Qingsong Fan, Shuiping Zhao, Danyan Xu, Christophe Morisseau, Nipavan Chiamvimonvat, Bruce D. Hammock

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Adipose tissue is the body largest free cholesterol reservoir and abundantly expresses ATP binding cassette transporter A1 (ABCA1), which maintains plasma high-density lipoprotein (HDL) levels. HDLs have a protective role in atherosclerosis by mediating reverse cholesterol transport (RCT). Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has various beneficial effects on cardiovascular disease. The sEH is highly expressed in adipocytes, and it converts epoxyeicosatrienoic acids (EETs) into less bioactive dihydroxyeicosatrienoic acids. We previously showed that increasing EETs levels with a sEH inhibitor (sEHI) (t-AUCB) resulted in elevated ABCA1 expression and promoted ABCA1-mediated cholesterol efflux from 3T3-L1 adipocytes. The present study investigates the impacts of t-AUCB in mice deficient for the low density lipoprotein (LDL) receptor (Ldlr-/- mice) with established atherosclerotic plaques. The sEH inhibitor delivered invivo for 4 weeks decreased the activity of sEH in adipose tissue, enhanced ABCA1 expression and cholesterol efflux from adipose depots, and consequently increased HDL levels. Furthermore, t-AUCB enhanced RCT to the plasma, liver, bile and feces. It also showed the reduction of plasma LDL-C levels. Consistently, t-AUCB-treated mice showed reductions in the size of atherosclerotic plaques. These studies establish that raising adipose ABCA1 expression, cholesterol efflux, and plasma HDL levels with t-AUCB treatment promotes RCT, decreasing LDL-C and atherosclerosis regression, suggesting that sEH inhibition may be a promising strategy to treat atherosclerotic vascular disease.

Original languageEnglish (US)
Pages (from-to)557-565
Number of pages9
JournalAtherosclerosis
Volume239
Issue number2
DOIs
StatePublished - Apr 1 2015

Fingerprint

Epoxide Hydrolases
ATP-Binding Cassette Transporters
Atherosclerosis
Cholesterol
HDL Lipoproteins
Atherosclerotic Plaques
LDL Lipoproteins
Adipocytes
Adipose Tissue
Acids
LDL Receptors
Vascular Diseases
Feces
Bile
Cardiovascular Diseases
4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid
Liver
Enzymes

Keywords

  • ABCA1
  • AcLDL
  • ATD
  • ATP binding cassette transporter A1
  • DHETs
  • EETs
  • Epoxyeicosatrienoic acids
  • HDL
  • High density lipoprotein
  • LSC
  • RCT
  • Reverse cholesterol transport
  • SCD
  • SEH
  • SEHI
  • Soluble epoxide hydrolase
  • T-AUCB

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis. / Shen, Li; Peng, Hongchun; Peng, Ran; Fan, Qingsong; Zhao, Shuiping; Xu, Danyan; Morisseau, Christophe; Chiamvimonvat, Nipavan; Hammock, Bruce D.

In: Atherosclerosis, Vol. 239, No. 2, 01.04.2015, p. 557-565.

Research output: Contribution to journalArticle

Shen, Li ; Peng, Hongchun ; Peng, Ran ; Fan, Qingsong ; Zhao, Shuiping ; Xu, Danyan ; Morisseau, Christophe ; Chiamvimonvat, Nipavan ; Hammock, Bruce D. / Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis. In: Atherosclerosis. 2015 ; Vol. 239, No. 2. pp. 557-565.
@article{5f281762bc8d4f05bb6cf5d2a129c732,
title = "Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis",
abstract = "Adipose tissue is the body largest free cholesterol reservoir and abundantly expresses ATP binding cassette transporter A1 (ABCA1), which maintains plasma high-density lipoprotein (HDL) levels. HDLs have a protective role in atherosclerosis by mediating reverse cholesterol transport (RCT). Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has various beneficial effects on cardiovascular disease. The sEH is highly expressed in adipocytes, and it converts epoxyeicosatrienoic acids (EETs) into less bioactive dihydroxyeicosatrienoic acids. We previously showed that increasing EETs levels with a sEH inhibitor (sEHI) (t-AUCB) resulted in elevated ABCA1 expression and promoted ABCA1-mediated cholesterol efflux from 3T3-L1 adipocytes. The present study investigates the impacts of t-AUCB in mice deficient for the low density lipoprotein (LDL) receptor (Ldlr-/- mice) with established atherosclerotic plaques. The sEH inhibitor delivered invivo for 4 weeks decreased the activity of sEH in adipose tissue, enhanced ABCA1 expression and cholesterol efflux from adipose depots, and consequently increased HDL levels. Furthermore, t-AUCB enhanced RCT to the plasma, liver, bile and feces. It also showed the reduction of plasma LDL-C levels. Consistently, t-AUCB-treated mice showed reductions in the size of atherosclerotic plaques. These studies establish that raising adipose ABCA1 expression, cholesterol efflux, and plasma HDL levels with t-AUCB treatment promotes RCT, decreasing LDL-C and atherosclerosis regression, suggesting that sEH inhibition may be a promising strategy to treat atherosclerotic vascular disease.",
keywords = "ABCA1, AcLDL, ATD, ATP binding cassette transporter A1, DHETs, EETs, Epoxyeicosatrienoic acids, HDL, High density lipoprotein, LSC, RCT, Reverse cholesterol transport, SCD, SEH, SEHI, Soluble epoxide hydrolase, T-AUCB",
author = "Li Shen and Hongchun Peng and Ran Peng and Qingsong Fan and Shuiping Zhao and Danyan Xu and Christophe Morisseau and Nipavan Chiamvimonvat and Hammock, {Bruce D.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.atherosclerosis.2015.02.014",
language = "English (US)",
volume = "239",
pages = "557--565",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Inhibition of soluble epoxide hydrolase in mice promotes reverse cholesterol transport and regression of atherosclerosis

AU - Shen, Li

AU - Peng, Hongchun

AU - Peng, Ran

AU - Fan, Qingsong

AU - Zhao, Shuiping

AU - Xu, Danyan

AU - Morisseau, Christophe

AU - Chiamvimonvat, Nipavan

AU - Hammock, Bruce D.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Adipose tissue is the body largest free cholesterol reservoir and abundantly expresses ATP binding cassette transporter A1 (ABCA1), which maintains plasma high-density lipoprotein (HDL) levels. HDLs have a protective role in atherosclerosis by mediating reverse cholesterol transport (RCT). Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has various beneficial effects on cardiovascular disease. The sEH is highly expressed in adipocytes, and it converts epoxyeicosatrienoic acids (EETs) into less bioactive dihydroxyeicosatrienoic acids. We previously showed that increasing EETs levels with a sEH inhibitor (sEHI) (t-AUCB) resulted in elevated ABCA1 expression and promoted ABCA1-mediated cholesterol efflux from 3T3-L1 adipocytes. The present study investigates the impacts of t-AUCB in mice deficient for the low density lipoprotein (LDL) receptor (Ldlr-/- mice) with established atherosclerotic plaques. The sEH inhibitor delivered invivo for 4 weeks decreased the activity of sEH in adipose tissue, enhanced ABCA1 expression and cholesterol efflux from adipose depots, and consequently increased HDL levels. Furthermore, t-AUCB enhanced RCT to the plasma, liver, bile and feces. It also showed the reduction of plasma LDL-C levels. Consistently, t-AUCB-treated mice showed reductions in the size of atherosclerotic plaques. These studies establish that raising adipose ABCA1 expression, cholesterol efflux, and plasma HDL levels with t-AUCB treatment promotes RCT, decreasing LDL-C and atherosclerosis regression, suggesting that sEH inhibition may be a promising strategy to treat atherosclerotic vascular disease.

AB - Adipose tissue is the body largest free cholesterol reservoir and abundantly expresses ATP binding cassette transporter A1 (ABCA1), which maintains plasma high-density lipoprotein (HDL) levels. HDLs have a protective role in atherosclerosis by mediating reverse cholesterol transport (RCT). Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has various beneficial effects on cardiovascular disease. The sEH is highly expressed in adipocytes, and it converts epoxyeicosatrienoic acids (EETs) into less bioactive dihydroxyeicosatrienoic acids. We previously showed that increasing EETs levels with a sEH inhibitor (sEHI) (t-AUCB) resulted in elevated ABCA1 expression and promoted ABCA1-mediated cholesterol efflux from 3T3-L1 adipocytes. The present study investigates the impacts of t-AUCB in mice deficient for the low density lipoprotein (LDL) receptor (Ldlr-/- mice) with established atherosclerotic plaques. The sEH inhibitor delivered invivo for 4 weeks decreased the activity of sEH in adipose tissue, enhanced ABCA1 expression and cholesterol efflux from adipose depots, and consequently increased HDL levels. Furthermore, t-AUCB enhanced RCT to the plasma, liver, bile and feces. It also showed the reduction of plasma LDL-C levels. Consistently, t-AUCB-treated mice showed reductions in the size of atherosclerotic plaques. These studies establish that raising adipose ABCA1 expression, cholesterol efflux, and plasma HDL levels with t-AUCB treatment promotes RCT, decreasing LDL-C and atherosclerosis regression, suggesting that sEH inhibition may be a promising strategy to treat atherosclerotic vascular disease.

KW - ABCA1

KW - AcLDL

KW - ATD

KW - ATP binding cassette transporter A1

KW - DHETs

KW - EETs

KW - Epoxyeicosatrienoic acids

KW - HDL

KW - High density lipoprotein

KW - LSC

KW - RCT

KW - Reverse cholesterol transport

KW - SCD

KW - SEH

KW - SEHI

KW - Soluble epoxide hydrolase

KW - T-AUCB

UR - http://www.scopus.com/inward/record.url?scp=84923352325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923352325&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2015.02.014

DO - 10.1016/j.atherosclerosis.2015.02.014

M3 - Article

VL - 239

SP - 557

EP - 565

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -